Correction: Beni-Suef Univ J Basic Appl Sci (2023) 12:104 https://doi.org/10.1186/s43088-023-00442-0
The authors would like to inform the readership that this article, published in November 2023, presents the first part of our research on the use of DPP-4 and SGLT-2 inhibitors in Egyptian diabetic patients. Part two of this research, which studies the prolonged impact of the medications discussed in this paper, can be found in [1].
Reference
Zakaraia HG, Salem HF, Mostafa MAA, Ali AM, Rabea H (2023) Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial. Eur Rev Med Pharmacol Sci. https://doi.org/10.26355/eurrev_202308_33300
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zakaraia, H.G., Salem, H.F., Mostafa, M.A.A. et al. Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial. Beni-Suef Univ J Basic Appl Sci 13, 32 (2024). https://doi.org/10.1186/s43088-024-00487-9
Published:
DOI: https://doi.org/10.1186/s43088-024-00487-9